Momenta Pharma (MNTA) : Mylan (MYL) receives FDA approval for a substitutable generic version of Teva's Copaxone

Momenta Pharmaceuticals, Inc.

• Founded: 2001
• Headquarters: Cambridge, MA
• momentapharma.com

MNTA  plunginges after Mylan (MYL) receives FDA approval for a substitutable generic version of Teva's Copaxone 40 mg/mL; Momenta currently has an application for a generic version of Teva's (TEVA) three-times-a-week COPAXONE 40 mg under review by the FDA)

  

• 2 days later: